Pershing Square Up 25% In First Half

Jul 3 2014 | 7:35am ET

Pershing Square Capital Management surged in the first half, banishing memories of a difficult—if ultimately successful—2013.

The New York-based hedge fund added 2.4% in June to finish the first six months of 2014 up 25%, it told clients. The returns make the $14.7 billion firm one of the few hedge funds to be handily beating the broader markets this year; the Standard & Poor’s 500 Index rose 6.1% in the first half.

Unlike last year, when Pershing Square’s most prominent investment—a $1 billion short against Herbalife—weighed heavily on returns, this year’s headline bet has been a big winner: Shares of Allergan Inc., which makes Botox, have soared since the hedge fund announced a nearly 10% stake in the company earlier this year.

Pershing Square is working with Valeant Pharmaceuticals International on the latter’s $53 billion bid for Allergan. Valeant has launched a hostile tender offer for the company, while Pershing Square is seeking the ouster of a majority of its board.

Pershing Square has also trimmed its losses on Herbalife this year after several probes into the company, which hedge fund founder William Ackman says is a pyramid scheme, were launched.


In Depth

GSAM’s Papagiannis on Liquid Alternatives

May 25 2016 | 5:07pm ET

The popularity of liquid alternatives strategies has blossomed in recent years,...

Lifestyle

From Modern Trader: Stephen Curry is a Black Swan

May 18 2016 | 7:43pm ET

What do the rise of the Internet, the sinking of the Titanic, 9/11, and Stephen...

Guest Contributor

LendingClub and the Question of Internal Hedge Funds

May 19 2016 | 8:42pm ET

Peer-to-peer lending platform LendingClub Corp. has been in the news since the firm...